Showing 21 - 30 of 47
Persistent link: https://www.econbiz.de/10004883392
Persistent link: https://www.econbiz.de/10004923252
Cambodia is expected to graduate from Least Developed Country status soon, at which time it will be required to make patents available for pharmaceutical products and processes to meet its obligations under the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS). Given its...
Persistent link: https://www.econbiz.de/10014563907
The United States government is running a campaign to characterize other industrialized countries as free riding on high U.S. pharmaceutical prices and innovation in new drugs. The campaign is based on the argument that lower prices imposed by price controls in these countries do not pay for...
Persistent link: https://www.econbiz.de/10013081855
This paper presents a historical perspective on the evolution of relationships between the pharmaceutical industry and physicians in two countries, the United States and Finland. Despite divergence early the twentieth century, and the absence of any large pharmaceutical firms based in Finland,...
Persistent link: https://www.econbiz.de/10012959491
Persistent link: https://www.econbiz.de/10003878693
Canada has strengthened intellectual property (IP) protections for pharmaceutical drugs several times over the last three decades. These changes were intended to lengthen the period of market exclusivity for new brand drugs and thereby allow them to earn additional sales revenues that could be...
Persistent link: https://www.econbiz.de/10011272321
Objectives This paper investigates the pricing strategy (perfect flat pricing, perfect monotonic pricing, intermediate) used for multiple dosage medications listed in the Ontario Drug Benefit Formulary.Methods All multiple dosage solid medications containing a single active ingredient newly...
Persistent link: https://www.econbiz.de/10005077616
In light of debates about the relationship between interests and scientific expert judgments, and the potential for declarations of conflict of interest (COI) to minimize corporate bias, we reviewed the approach to COI in 3 European drug regulatory bodies. These bodies were the Irish Medicines...
Persistent link: https://www.econbiz.de/10008593991
Cambodia is expected to graduate from Least Developed Country status soon, at which time it will be required to make patents available for pharmaceutical products and processes to meet its obligations under the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS). Given its...
Persistent link: https://www.econbiz.de/10014541559